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Objectives: Prognostic research in patients with peripheral arterial disease (PAD) is scarce and deter-
minants of outcome are mainly studied in males. The current management of PAD in women is based on
evidence from, at best, mixed populations. We therefore assessed risk and prognostic factors in 313 men
and 169 women from the Dutch Bypass Oral anticoagulants or Aspirin Study of whom long-term follow-
up data were available.
Method: The primary composite outcome event was vascular death, myocardial infarction, stroke, or
major amputation during 5 years of follow-up. Variables with a p-value <0.2 in the univariate analyses
were added to the multivariate Cox proportional hazards model.
Results: Females were older (71 vs. 68 years; p < 0.01), had more advanced PAD (critical limb ischemia
(CLI) 52.1 vs. 42.2%; p ¼ 0.04), more often had peripheral bypass surgery as primary intervention (50.5 vs.
32.5%; p < 0.01), and had more often hypertension (48.5 vs. 33.2%; p < 0.01) than males. Males were
more often smokers (63.6 vs. 53.3%; p ¼ 0.03) and had more prior myocardial infarctions (18.5 vs. 10.1%;
p ¼ 0.02).
In total 170 events occurred, 74 (44%) in females and 96 (31%) in males. Overall, independent risk factors
for the primary outcome event were age and critical limb ischemia. Independent risk factors in males
were: age (HR: 1.06, 95% CI: 1.03e1.09), critical limb ischemia (HR: 1.7, 95% CI: 1.05e2.7), and diabetes
mellitus (HR: 1.7, 95% CI: 1.01e2.8) and in females critical limb ischemia (HR: 3.5, 95% CI: 2.0e6.1),
ABI0.9 (HR: 2.8, 95% CI: 1.2e6.1), and femorocrural bypass (HR: 1.9, 95% CI: 1.1e3.3). Although sex
was not an independent risk factor in the overall analysis, women younger than 60 years had an
increased risk for cardiovascular events compared to men of that age (HR: 4.9, 95% CI: 1.8e13.6), whereas
no difference was seen above 60 years of age.
Conclusions: Risk factors for cardiovascular events in patients with PAD differ between men and women.
To our knowledge, this is the ﬁrst study that shows such a bad outcome in female patients younger than
60 years of age. More awareness leading to early diagnosis and optimal treatment might improve long-
term clinical outcome in (young) women with PAD.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Patients with peripheral arterial disease (PAD) have greater
functional impairments and higher risk of fatal and non-fatal
cardiovascular events compared with patients with symptomatic
atherosclerosis in other vascular beds such as coronary, carotid and
cerebral arteries.1,2 Yet, PAD is under-recognized by physicians,
allied health-care professionals and the public.1,2
The prevalence of PAD is slightly greater in men than in women,
particularly in the younger age groups. In patients with intermit-
tent claudication (IC), the ratio of men to women ranges between
1:1 and 2:1. However, the prevalence of PAD in women increases
rapidly beyond 40 years of age from 3 to 4.4% up to 15.5e29% at the
age of 80 years and older.3,4tions on this paper, please go
: þ31 88 755 5017.
isman).
ciety for Vascular Surgery. PublisheLong-term prognostic research in patients with PAD is scarce
and outcome determinants have mainly been studied in males.1,3e8
Due to a lower prevalence of PAD in young women compared with
older women and men, even less is known about risk factors and
prognostic factors of the long-term outcome in pre-menopausal
women with PAD.6e8
The current management of PAD inwomen is based on evidence
from, at best, mixed populations. As there are differences in
etiology, presentation and outcome betweenmen andwomenwith
atherosclerosis,6e8 the management of PAD might have to be
adjusted for women, in accordance with the sex-inﬂuenced
management of coronary arterial disease.9,10
To determine whether sex and age-driven management of PAD
is indicated, large prospective studies about the differences
between men and women with PAD are required. We therefore
assessed risk and prognostic factors ofmen andwomenwith PAD ind by Elsevier Ltd. All rights reserved.
Table 1
Baseline variables.
Overall
N ¼ 482
Men
N ¼ 313
Women
N ¼ 169
P-value
Demographic characteristics
Age (mean  SD) 68.8  9.7 67.7  9.7 70.7  10.2 0.002
Male 313 (64.9%) e e e
Female 169 (35.1%) e e e
Medical History
Diabetes mellitus 109 (22.6%) 65 (20.8%) 44 (26.0%) 0.210
Smoking 289 (60.0%) 199 (63.6%) 90 (53.3%) 0.032
Hypertension 186 (38.6%) 104 (33.2%) 82 (48.5%) 0.001
Hyperlipidemia 101 (21.0%) 65 (20.8%) 36 (21.3%) 0.907
Angina pectoris 80 (16.6%) 47 (15.0%) 33 (19.5%) 0.248
Myocardial infarction 75 (15.6%) 58 (18.5%) 17 (10.1%) 0.017
TIA/CVA 49 (10.2%) 27 (8.6%) 22 (13.0%) 0.155
Claudication
AB index (mean  SD) 0.55  0.37 0.56  0.37 0.52  0.37 0.370
ABI 0.9 450 (93.4%) 292 (93.3%) 158 (93.5%) 1.000
ABI 0.6 288 (59.8%) 177 (56.5%) 111 (65.7%) 0.052
CLI 220 (45.6%) 132 (42.2%) 88 (52.1%) 0.044
Vascular intervention 213 (44.2%) 158 (50.5%) 55 (32.5%) 0.000
Trial Bypass
Femorocrural/pedal bypass 107 (22.2%) 76 (24.3%) 31 (18.3%) 0.168
Venous bypass 313 (64.9%) 210 (67.1%) 103 (60.9%) 0.194
Trial Medication
Aspirin 243 (50.4%) 151 (48.2%) 92 (54.4%) 0.195
Anticoagulants 239 (49.6%) 162 (51.8%) 77 (45.6%)
Demographic characteristics, medical history and intervention-related variables of
all patients and stratiﬁed by sex. Differences in dichotomous baseline variables
between men and women were analyzed with chi-square tests, differences in
continuous variables with Student t-tests.
AB index: ankle brachial pressure index, ABI 0.9: ankle brachial pressure index
below 0.9; ABI0.6: ankle brachial pressure index below 0.6; vascular intervention:
previous vascular intervention at baseline; TIA/CVA: transient ischemic attack or
cerebrovascular accident; CLI: critical limb ischemia.
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Aspirin (BOA) Study.11
Methods
Patients
The present longitudinal cohort study is derived from the Dutch
BOA Study. Full details of this multicentre prospective randomized
trial have been published elsewhere,11 and are brieﬂy summarized
here. From 1995 until 1998, 2690 patients were included from 77
vascular centers throughout the Netherlands after infrainguinal
bypass surgery. To study the effects of oral anticoagulants and
aspirin in preventing bypass occlusion, lower limb amputation and
ischemic events, these patients were randomly allocated to oral
anticoagulation (target international normalized ratio (INR)
3.0e4.5) or to aspirin (100 mg carbasalate calcium daily).
For the long-term follow-up study we included all patients from
the six sites that contributed most patients in the study (18%,
n ¼ 482). Based on the event rate in the Dutch BOA Study, the
resulting sample size was sufﬁcient to allow for the development of
robust prediction models.
The Ethics Committee of the University Medical Centre Utrecht
approved this follow-up study.
Data collection
During the Dutch BOA Study, follow-up visits took place at 3 and
6 months after surgery and every 6 months thereafter for
prospective registration of outcome events. For the subsequent
long-term follow-up of the BOA Study, outcome events and drug
use of patients who were still alive at their last follow-up visit in
April 1998 were collected until August 2009 in a stepwise manner.
First, follow-up data were obtained from the study record and from
the patients’ attending vascular surgeon. Second, the patients’
general practitioner was approached for similar information if data
from the vascular surgeon were incomplete. Third, the patient was
interviewed about the occurrence of outcome events if data
remained incomplete at the general practitioner. In case the patient
had died, relatives or acquaintances were approached for follow-up
data. If the patient hadmoved, the last known residencewas looked
up at the municipality register to trace the patient’s new home
address. If the patient or their relatives or acquaintances did not
respond, the registry ofﬁce was contacted to inquire whether the
patient had died and when.
To conﬁrm a reported outcome event, clinical data speciﬁc for
that event were gathered from the attended hospital and/or
specialist (e.g., discharge letters, laboratory reports, 12-lead elec-
trocardiogram, reports of Doppler or duplex scans, brain scan
reports, operation reports and autopsy reports). All participating
patients alive at time of our approach gave informed consent on
completing our follow-up data.
Outcome events
The primary outcome event was the composite of vascular
death, non-fatal myocardial infarction, non-fatal ischemic stroke or
major lower limb amputation (whichever occurred ﬁrst) within 5
years from inclusion. The deﬁnitions of outcome events are
summarized in Appendix A. Each recorded outcome event was
adjudicated and classiﬁed according to the pre-speciﬁed deﬁnitions
by a panel consisting of a vascular surgeon, a clinical epidemiolo-
gist, a neurologist and a cardiologist. Discrepancies were resolved
by discussion and documented in a logbook to ensure consistent
adjudication of the outcome events.Statistical analyses
Continuous variables were summarized as mean with standard
deviation (SD), and discrete variables were summarized as
frequency and percentage. Missing ankle brachial pressure index
(ABI) data of 81 patients were imputedwith single linear regression
analysis.
All analyses were performed in three patient groups based on
sex and age: 1) overall analyses (includes all patients), 2) patients
under 60 years of age and 3) female patients.
Differences in dichotomous baseline variables between the
different subgroups were analyzed with chi-square tests, and
differences in continuous variables with Student’s t-tests.
Cumulative risk of mortality and vascular events, and risk
factors of the primary outcome event were calculated with a Cox
proportional hazards model and numerically presented as adjusted
hazard ratios (HRs) with corresponding 95% conﬁdence intervals
(CIs) and presented graphically as KaplaneMeier curves. Variables
with a p-value <0.2 in the univariate analyses were added to the
multivariate model in a forward stepwise manner.Results
Overall analyses
Baseline variables
Demographic characteristics, medical history and intervention-
related variables of all patients and stratiﬁed by sex are shown in
Table 1. Of the 482 patients, 169 (35.1%) were female. Female
patients were older (71 vs. 68 years; p < 0.01), had more advanced
PAD (critical limb ischemia (CLI) 52.1 vs. 42.2%; p ¼ 0.04), more
Table 3
Independent risk factors for cardiovascular death, myocardial infarction, transient
ischemic attack or cerebrovascular accident, and major amputation of all patients
and stratiﬁed by sex.
Independent risk factors
Cardiovascular death
Overall analysis
111 events
Age: HR: 1.074; 95%CI: 1.047e1.101
Diabetes mellitus: HR: 1.54; 95%CI: 1.03e2.30
CLI: HR: 2.22; 95%CI: 1.47e3.36
All men
65 events
Age: HR: 1.085; 95%CI: 1.053e1.119
Diabetes mellitus: HR: 2.23; 95%CI: 1.33e3.72
All women
46 events
Age: HR: 1.052; 95%CI: 1.010e1.096
ABI<0.9: HR: 4.23; 95%CI: 1.73e10.37
CLI: HR: 3.62; 95%CI: 1.67e7.83
Fem-crur bypass: HR: 2.08; 95%CI: 1.06e4.08
Myocardial infarction
Overall analysis
34 events
Myocardial infarction: HR: 2.53; 95%CI: 1.21e5.29
All men
21 events
Myocardial infarction: HR: 2.57; 95%CI: 1.04e6.38
All women
13 events
Fem-crur bypass: HR: 4.01; 95%CI: 1.30e12.31
TIA/CVA
Overall analysis
28 events
Age: HR: 1.062; 95%CI: 1.016e1.110
All men
17 events
Age: HR: 1.106; 95%CI: 1.037e1.179
All women
11 events
No independent risk factors for TIA/CVA
Major amputation
Overall analysis
46 events
Diabetes mellitus: HR: 2.58; 95%CI: 1.44e4.62
CLI: HR: 8.03; 95%CI: 3.04e21.18
Fem-crur bypass: HR: 2.32; 95%CI: 1.27e4.24
All men Diabetes mellitus: HR: 2.52; 95%CI: 1.13e5.62
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vs. 32.5%; p < 0.01) and had more often hypertension (48.5 vs.
33.2%; p < 0.01) as compared with males. More male patients were
smokers (63.6 vs. 53.3%; p ¼ 0.03), and had myocardial infarctions
(18.5 vs. 10.1%; p ¼ 0.02) in comparison with females.
Outcome events
Over a median follow-up of 5 years (SD: 1.4; mean: 4.2) 170
(35.3%) primary outcome events occurred, 74 (44%) events in
females and 96 (31%) events in males (Table 2). We lost two (0.4%)
patients to follow-up after 2.6 and 4.6 years, respectively. The
composite primary outcome mostly included vascular death
(n ¼ 76, 44.7%) and major lower limb amputation (n ¼ 46, 27.1%).
Non-fatal myocardial infarction (n ¼ 26, 15.3%) and non-fatal
ischemic stroke (n ¼ 22, 12.9%), respectively, occurred less
frequently (Table 3). Overall, independent risk factors for the
primary outcome event were age (HR: 1.045, 95% CI: 1.024e1.068)
and CLI (HR: 2.33, 95% CI: 1.63e3.35).
Although sex was not an independent risk factor (HR: 1.09; 95%
CI: 0.77e1.54) in the overall analyses, signiﬁcant differences were
seen in risk factors between men and women. Independent risk
factors for the primary outcome event in males were age (HR: 1.06,
95% CI: 1.03e1.09), CLI (HR: 1.7, 95% CI: 1.05e2.7) and diabetes
mellitus (HR: 1.7, 95% CI: 1.01e2.8). Independent risk factors in
females were CLI (HR: 3.5, 95% CI: 2.0e6.1), ABI  0.9 (HR: 2.8, 95%
CI: 1.2e6.1) and femorocrural bypass (HR: 1.9, 95% CI: 1.1e3.3).
Study treatment, aspirin or oral anticoagulants was not an inde-
pendent risk factor for the primary outcome event or for any of the
individual components.
Event-free survival curves for the primary outcome event for
men and women are shown in Fig. 1.Table 2
Independent risk factors for the primary outcome event of all patients and stratiﬁed
by sex.
Independent risk factors for the primary
outcome event
Overall analyses
170 events
Age (HR: 1.045, 95% CI: 1.024e1.068)
CLI (HR: 2.33, 95% CI: 1.63e3.35)
All men
96 events
Age (HR: 1.06, 95% CI: 1.03e1.09)
Diabetes mellitus (HR: 1.7, 95% CI: 1.01e2.8)
CLI (HR: 1.7, 95% CI: 1.05e2.7)
All women
74 events
ABI0.9 (HR: 2.8, 95% CI: 1.2e6.1)
CLI (HR: 3.5, 95% CI: 2.0e6.1)
Femorocrural bypass (HR: 1.9, 95% CI: 1.1e3.3)
Patients under 60 years
of age
16 events
Female (HR: 4.9, 95% CI: 1.8e13.6)
Hypertension (HR: 3.3, 95% CI: 1.2e9.2)
CLI (HR: 4.2, 95% CI: 1.5e12.0)
Patients over 60 years
of age
154 events
Age (HR: 1.046; 95%CI: 1.019e1.074)
TIA/CVA (HR: 1.6; 95%CI: 1.0e2.4)
CLI (HR: 2.4; 95%CI: 1.7e3.4)
Male patients under
60 years of age
7 events
No independent risk factors for the primary
outcome
Female patients under
60 years of age
9 events
CLI (HR: 5.01, 95% CI: 1.35e19.15)
Male patients over
60 years of age
89 events
DM (HR: 2.0; 95%CI: 1.2e3.1)
CLI (HR: 2.0; 95%CI: 1.3e3.0)
Venous bypass (HR: 1.9; 95%CI: 1.1e3.2)
Female patients over
60 years of age
65 events
Age (HR: 1.06, 95% CI: 1.01e1.10)
CLI (HR: 3.47, 95% CI: 1.90e6.33)
ABI<0.9 (HR: 2.37, 95% CI: 1.02e5.52)
ABI 0.9: ankle brachial pressure index below 0.9; TIA/CVA: transient ischemic
attack or cerebrovascular accident; CLI: critical limb ischemia.
25 events CLI: HR: 5.78; 95%CI: 1.54e21.68
Fem-crur bypass: HR: 4.01; 95%CI: 1.55e10.43
All women
21 events
CLI: HR: 11.34; 95%CI: 2.63e48.73
ABI 0.9: ankle brachial pressure index below 0.9; TIA/CVA: transient ischemic
attack or cerebrovascular accident; CLI: critical limb ischemia.Analyses of patients under 60 years of age
Baseline variables
Overall, 27 (27.9%) females and 70 (72.1%) males were younger
than 60 years. Young women more often had prior vascular inter-
ventions than young men (59.3% vs. 22.9%, p < 0.01).Figure 1. KaplaneMeier curves stratiﬁed by sex. Women (N ¼ 169) and men (N ¼ 313).
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Sixteen (16.5%) primary outcome events occurred, of which nine
(33.3%) events in females and seven (10.0%) events in males.
Sex was an independent risk factor for the primary outcome
event in young patients, but not in patients above 60 years of age.
Women younger than 60 years had a ﬁvefold increased risk for the
primary outcome event compared with men from in the same age
category (HR: 4.9, 95% CI: 1.8e13.6), whereas no difference was
seen in patients above 60 years of age (HR: 0.99, 95% CI: 0.7e1.4).
Other independent risk factors for the primary outcome event in
young patients were CLI (HR: 4.2, 95% CI: 1.5e12.0) and hyper-
tension (HR: 3.3, 95% CI: 1.2e9.2).
Fig. 2 shows the event-free survival curves for men 60 years,
men >60 years, women 60 years and women >60 years.
Analyses of female patients
Baseline variables
The mean age difference between women under and above 60
years was 22.15 years. When compared with women older than 60
years, young women smoked more often (85.2% vs. 47.5%; p < 0.01)
and more often had prior vascular interventions (59.3% vs. 30.5%;
p< 0.01). Women older than 60 years more often had CLI (57.4% vs.
25.9%; p< 0.01), angina pectoris (23.4% vs. 0%; p ¼ 0.03) and an ABI
< 0.6 (68.8% vs. 48.1%; p ¼ 0.048).
Outcome events
In all female patients 74 (43.8%) primary outcome events
occurred, nine (33.3%) events in young women and 65 (45.8%)
events in women above 60 years of age.
The independent risk factor in young women was CLI (HR: 5.01,
95% CI: 1.35e19.15).
Independent risk factors for the primary outcome event in
women above 60 years of age were CLI (HR: 3.47, 95% CI:
1.90e6.33), age (HR: 1.06, 95% CI: 1.01e1.10) and ABI < 0.9 (HR:
2.37, 95% CI: 1.02e5.52).
Discussion
We found differences in independent risk factors for cardio-
vascular complications between men and women with PAD. The
independent risk factors in males were age, CLI and diabetes mel-
litus. Independent risk factors in females were CLI, ABI < 0.9 and
femorocrural bypass. Sex itself was not an independent risk factor
for cardiovascular complications. However, among patients under
60 years of age the risk of a cardiovascular complication did
signiﬁcantly differ between men and women. Women under 60
years of agewith PAD had a ﬁvefold increased risk of cardiovascularFigure 2. KaplaneMeier curves stratiﬁed by age and sex. Women 60 years of age
(N ¼ 27), women >60 years of age (N ¼ 142), men 60 years of age (N ¼ 90), and men
>60 years of age (N ¼ 223).complications compared to men of that age; their prognosis is as
poor as in patients above 60 years with PAD. To our knowledge, this
is the ﬁrst study that shows a worse cardiovascular prognosis for
female patients aged less than 60 years.
Besides differences in independent risk factors for cardiovas-
cular complications, there were differences in baseline character-
istics between men and women who underwent peripheral bypass
surgery. Women were older (71 vs. 68 years), had more advanced
PAD (CLI 52.1 vs. 42.2%) and had more often hypertension (48.5 vs.
33.2%) as compared to men. More male patients were smokers
(63.6 vs. 53.3%), had myocardial infarctions (18.5 vs. 10.1%) and had
prior vascular interventions (50.5 vs. 32.5%) in comparison with
female patients.
The prevalence of PAD, either symptomatic or asymptomatic, is
slightly greater in men thanwomen, particularly in the younger age
groups.1,2 This explains the underrepresentation of women, espe-
cially young women, in current clinical studies on PAD.5 Moreover,
women undergoing peripheral bypass surgery tend to be older than
men.12 Our study population too had a relatively low number of
women included (N ¼ 169, 35.1%) of which only 16% were under 60
years (N ¼ 27).
In general, women more often have unrecognized PAD than
men, leading to more advanced PAD at the time of diagnosis and
a decreased likelihood of revascularization, and overall to a worse
prognosis in comparison with men.3,4,13 In accordance we found
women receiving peripheral bypass surgery were older, had more
advanced PAD at baseline, more often had peripheral bypass
surgery as primary intervention and had a worse prognosis (crude
HR: 1.53, 95% CI: 1.13e2.07) in comparison with men. For these
reasons, early recognition and diagnosis of PAD in women leading
to an earlier initial treatment may lead to an improved outcome.
Therefore, awareness and larger prospective cohort studies on PAD
in women are required, which might also clarify the reason for
a worse outcome in younger patients with PAD.
We hypothesized that estrogen levels might play a signiﬁcant role
in our patient population. Therefore, we wanted to compare patients
with pre- and post-menopausal developed PAD. Ideally, we would
have set the cut-off point at 50 years of age; however, the study pop-
ulation consisted of too few patients under 50 years of age to perform
properly powered analyses. Therefore, we set the cut-off point at 60
years of age so that we could analyze the effect of menopause.
Pre-menopausal women beneﬁt from an atheroprotective
environment throughmechanisms that are not totally understood.8
In relatively healthy vessels, estrogen prevents the development
and progression of atherosclerotic lesions, while in the presence of
established atherosclerotic plaques, estrogen fails to inhibit the
progression of atherosclerosis or may even trigger cardiovascular
events.14 This might explain the bad prognosis of young women
who develop PAD. Another explanation could be that unaccounted
factors that caused pre-menopausal PADmight lead to a high risk of
cardiovascular events, confounding our results.
Smoking might play a key role in the development of premature
PAD as we found a large number of young female patients who
smoke compared to women above 60 years of age. Diabetes mel-
litus has been suggested to be a more ominous marker for cardio-
vascular events in women than in men;8 however, our ﬁndings
suggest the opposite. Young women did not have more often dia-
betes mellitus, hypertension or hyperlipidemia than women above
60 years of age. We have, however, no clear explanation for this
observed inconsistency. Unfortunately, other known cardiovascular
risk factors such as bodymass index (BMI) and familial historywere
not registered at baseline.
The Dutch BOA Study was a pragmatic, real life, randomized
clinical trial in a large patient population, thus representing the
general Dutch and likely the European moderate to severe PAD
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a clinically relevant 5-year follow-up of a subset of BOA partici-
pants. Due to our thorough follow-up methodology, we had very
few patients lost to follow-up: in two (0.4%) patients follow-up data
were missing after 2.6 and 4.6 years, respectively. Possibly, recall
bias has occurred in the case of deceased patients whose relatives
or acquaintances were approached for follow-up data. However, we
screened all relevant clinical data sources from health-care
providers, to which we were referred to by relatives, in order to
minimize this.
Although peripheral bypass surgery is performed less frequently
inwomen than inmen, still 35.1% of our populationwas female. The
modest amount of young female patients is a limitation of our
study.
Conclusion
We showed that there are differences in risk factors between
men and women. Differences in risk factors indicate possible
differences in pathophysiology between men and women and
might advocate differential management of PAD. Possibly, more
aggressive risk factor control might improve the prognosis of
(young) women.
Furthermore, in the present analysis we found that young
women with PAD are at an increased risk of future cardiovascular
complications compared with men of that age. Further research on
this topic is necessary to conﬁrm our ﬁndings and shed light on
optimal management of PAD in women. For now, more awareness
leading to early diagnosis and optimal treatment might improve
long-term clinical outcome in (young) women with PAD.
Appendix. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.ejvs.2012.01.006.References
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